Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Walenga

Showing results (161-170 of 196) with videos related to

Pageof 20
Sort By:
Seminars in Thrombosis and Hemostasis|October 1, 1984
Cyanotic congenital heart disease in children: hemostatic disorders and relevance of molecular markers of hemostasisC R Suarez, C E Menendez, A J Griffin, et al.
International Angiology : a Journal of the International Union of Angiology|February 25, 2000
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methodsS Ahmad, O Iqbal, A Ahsan, et al.
Thrombosis Research|January 12, 2001
Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding siteG Yu, L LeBrun, N S Gunay, et al.
Thrombosis Research|April 4, 1998
Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of plateletsW P Jeske, J M Walenga, E Szatkowski, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Antithrombin agents: the new class of anticoagulant and antithrombotic drugsJ Fareed, B E Lewis, D D Callas, et al.
Progress in Cardiovascular Diseases|May 1, 1992
Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugsJ Fareed, P Bacher, H L Messmore, et al.
The Journal of Trauma|July 1, 1992
The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical stateA Kowal-Vern, R L Gamelli, J M Walenga, et al.
Clinics in Laboratory Medicine|March 1, 1995
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disordersJ Fareed, R L Bick, D A Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HITJ M Walenga, W P Jeske, D E Wallis, et al.
Journal of Medicinal Chemistry|June 1, 1990
Oligosaccharide mapping of low molecular weight heparins: structure and activity differencesR J Linhardt, D Loganathan, A al-Hakim, et al.
Pageof 20

Showing results (161-170 of 196) with videos related to

Sort By:
Pageof 20
Seminars in Thrombosis and Hemostasis|October 1, 1984
Cyanotic congenital heart disease in children: hemostatic disorders and relevance of molecular markers of hemostasisC R Suarez, C E Menendez, A J Griffin, et al.
International Angiology : a Journal of the International Union of Angiology|February 25, 2000
Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methodsS Ahmad, O Iqbal, A Ahsan, et al.
Thrombosis Research|January 12, 2001
Heparinase I acts on a synthetic heparin pentasaccharide corresponding to the antithrombin III binding siteG Yu, L LeBrun, N S Gunay, et al.
Thrombosis Research|April 4, 1998
Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of plateletsW P Jeske, J M Walenga, E Szatkowski, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 22, 2000
Antithrombin agents: the new class of anticoagulant and antithrombotic drugsJ Fareed, B E Lewis, D D Callas, et al.
Progress in Cardiovascular Diseases|May 1, 1992
Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugsJ Fareed, P Bacher, H L Messmore, et al.
The Journal of Trauma|July 1, 1992
The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical stateA Kowal-Vern, R L Gamelli, J M Walenga, et al.
Clinics in Laboratory Medicine|March 1, 1995
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disordersJ Fareed, R L Bick, D A Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|June 5, 1999
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HITJ M Walenga, W P Jeske, D E Wallis, et al.
Journal of Medicinal Chemistry|June 1, 1990
Oligosaccharide mapping of low molecular weight heparins: structure and activity differencesR J Linhardt, D Loganathan, A al-Hakim, et al.
Pageof 20